NCT07086404View on ClinicalTrials.gov

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

September 15, 2027

Study Completion Date

September 15, 2029

Conditions
Idiopathic Inflammatory Myopathy (IIM)
Interventions
DRUG

GC012F Injection infusion

GC012F Injection infusion will be performed within 48-72 hours after the end of lymphodepleting preconditioning.

All Listed Sponsors
collaborator

AstraZeneca Global R&D (China) Co., Ltd.

UNKNOWN

collaborator

Gracell Biotechnologies (Shanghai) Co., Ltd.

INDUSTRY

lead

Daishi Tian

OTHER